Five Challenges Bill Anderson Faces At Bayer
Replacing Werner Baumann As CEO
Executive Summary
Six weeks after leaving Roche, Bill Anderson is taking the helm at Bayer in one of the most intriguing appointments in the sector for some time.
You may also be interested in...
Xarelto Declines Are New Normal At Bayer
Sales of the blockbuster Factor Xa blood thinner Xarelto declined more steeply than was expected but Bayer’s second biggest seller Eylea is still performing well.
Women’s Health Still Key to Bayer Despite Early Research Shift
The German major has pinned its early-stage research colors to the masts of oncology, cardiovascular, neurology, rare diseases and immunology, representing a shift away from rather than an abandonment of women’s health.
Vir CEO George Scangos, Set To Retire, Reflects On A Long Career In Biotech
Bayer pharmaceuticals executive Marianne De Backer will succeed Scangos at Vir, tasked with advancing several mid-stage programs in areas like hepatitis B and influenza to late-stage development.